Objective To describe the subsequent reproductive outcome for a Danish nationwide cohort of women with peripartum cardiomyopathy (PPCM).
Introduction
Peripartum cardiomyopathy (PPCM) is characterised by idiopathic heart failure presenting towards the end of pregnancy or within 6 months following delivery. Left ventricular systolic function is impaired with left ventricular ejection fraction (LVEF) ≤ 45% and there is no other identifiable cause of heart failure, e.g. congenital or other pre-existing heart disease. 1 PPCM is associated with pre-eclampsia and shares pathophysiological mechanisms. 2, 3 Also, the nursing hormone prolactin seems to play a role in the development of heart failure, 4 and prolactin inhibition with bromocriptine is being explored and implemented as a therapeutic target. 5, 6 The incidence of PPCM varies geographically, ranging from 1:300 in Haiti 7 to 1:20 000 live births in Japan. 8 Following medical heart failure therapy, most women recover cardiac function partially or fully within 12 months after diagnosis [9] [10] [11] [12] and a full recovery rate of 72% has been reported. 12 Persistent heart failure is reported among 6-25% 9,12,13 with 0.5-16.5% mortality. 9, [12] [13] [14] [15] Before embarking on a new pregnancy, women who have suffered from PPCM need counselling on the potential maternal and perinatal health risk of a subsequent pregnancy. No clear guidelines exist and the literature is sparse. However, it appears that the risk of relapse in a subsequent pregnancy depends on whether LVEF has recovered or not; reported relapse rates are 27% if the LVEF is normal before a subsequent pregnancy and 48% if LVEF is still impaired. 16 Early termination of pregnancy in women with heart failure may prevent relapse, 16 but data on terminations as well as perinatal outcomes are very limited in women with previous PPCM.We, therefore, aimed to describe all subsequent reproductive outcomes in a Danish nationwide cohort of women diagnosed with PPCM during 2005À2014.
Methods
Women diagnosed with PPCM in a 10-year period from 1 January 2005 to 31 December 2014 were identified in the nationwide Medical Birth Registry and Danish National Patient Registry, where all hospital contacts have been recorded and coded according to the International Classification of Diagnoses (ICD) since 1973 and 1977, respectively. A unique personal identification number allows linkage between registries and retrieval of patient records. A broad search strategy including ICD-10 diagnoses of peripartum cardiomyopathy, any other cardiomyopathy and heart failure in temporal relation to a delivery were applied and original patient records were then retrieved in order to validate the PPCM diagnosis according to the European Society of Cardiology and the inclusion criteria of the EURObservational Research Programme PPCM registry, 17 and to collect additional clinical data. This combined approach resulted in the identification of 61 women with a validated PPCM diagnosis as previously described in the parent cohort study. 18 We then performed a second search in the two nationwide registries to identify all subsequent reproductive outcomes from 1 January 2005 to 30 June 2016 for these 61 women. We searched ICD-10 codes for deliveries (O80-O84), terminations and miscarriages (O00-O08), and female sterilisations (KLGA22) in the study population. Additional information on the subsequent pregnancies and sterilisations were obtained through review of medical records ( Figure S1 ). Baseline data including the timing of PPCM diagnosis, information on clinical management and clinical course of PPCM, degree of and time to recovery, history of pre-eclampsia or hypertensive disorders of pregnancy, comorbidity, parity and ethnicity were available from the parent study, and the following new data were retrieved from the medical records: interval between pregnancies, LVEF before, during and after the subsequent pregnancy, clinical course and management throughout the subsequent pregnancy, mode of delivery, obstetric complications, breastfeeding, pharmacological cessation of lactation/inhibition of prolactin, content of prepregnancy counselling, and reason for pregnancy terminations and sterilisations when noted. In addition, we sought information on neonatal outcomes including gestational age at delivery, birthweight, birth length, congenital malformations, and neonatal morbidity. If a woman had more than one subsequent pregnancy, we reported the interval between pregnancies as the time from PPCM diagnosis to the first subsequent pregnancy.We defined the PPCM pregnancy as the index pregnancy and all later pregnancies as subsequent pregnancies. Complete recovery of heart function was defined as LVEF ≥ 55%. Relapse of heart failure during a subsequent pregnancy was defined as a decrease of LVEF ≤ 45%. Symptoms of heart failure were classified in accordance with the four New York Heart Association (NYHA) functional classes of heart failure. 19 Gestational hypertension was defined as onset of hypertension after 20 weeks of gestation with systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg and no significant proteinuria, whereas pre-eclampsia was defined as onset after 20 weeks of gestation of SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg with significant proteinuria (≥0.3 g/24 hours or ≥1+ on urine dipstick). 20 Data are presented as mean AE standard deviation (SD) or median (range) for continuous data as appropriate and as proportions for categorical data. Continuous and categorical variables were compared between the 61 women with and without a subsequent pregnancy using a t-test for normally distributed continuous variables and Chi-square test or Fisher's exact test for categorical variables as appropriate.
Continuous and categorical variables were compared between the 13 women, who either continued with a subsequent pregnancy beyond 20 weeks or had an early termination, using the Mann-Whitney test for continuous variables and Fisher's exact test for categorical variables. A two-sided P-value <0.05 was considered statistically significant.
Statistical analyses were performed using SAS Enterprise Guide 7.1 (SAS Institute Inc., Cary, NC, USA).
The 27.2015) . According to Danish law, these approvals give access to medical records without additional informed consent from the patient. seven early terminations, and one ectopic pregnancy. One woman had two early terminations and one ectopic pregnancy. Another woman, who gave birth to a liveborn child, also had a miscarriage. Seven pregnancies continued beyond 20 weeks of gestation and resulted in a liveborn child.
Index pregnancy characteristics of the parent cohort of 61 women with PPCM by any subsequent pregnancy are presented in Table 1 . Women with a subsequent pregnancy seemed to be younger and have a higher baseline LVEF at PPCM diagnosis (P = 0.09).
Baseline characteristics of the 13 women with subsequent pregnancies are shown in Table 2 . All were categorised as being in New York Heart Association (NYHA) functional class I when they entered the subsequent pregnancy, and LVEF, at this time point, did not differ between women who had an early termination and women who continued with their pregnancy after 20 weeks. All the women (6/6, 100%) who had an early termination of pregnancy had been advised against a subsequent pregnancy after the PPCM diagnosis, compared with 2/7 women (29%), who continued their pregnancy beyond 20 weeks (P = 0.061).
Six women had a total of seven early terminations. Three of the six women were still on heart failure medication at the time of conception in the subsequent pregnancy at a median of 29 months (range 4-48 months) after their PPCM diagnosis. All the pregnancies were terminated in the first trimester with a median gestational age of 48 days (range 43-51). The cause given for terminating the pregnancy was the risk of heart failure relapse for all women. None experienced any cardiac complications in the short pregnancies.
Maternal and perinatal outcomes in the subsequent pregnancy for the seven women continuing a pregnancy beyond 20 weeks of gestation are shown in Table 3 . The median time from PPCM diagnosis to the subsequent pregnancy was 32 months (range 26-76). One of the women had a short episode of self-limiting nodal tachycardia in relation to fever, but no other cardiac events were noted during pregnancy. None experienced a relapse of hypertensive disorders of pregnancy.Two were on beta-blocker treatment before and throughout the subsequent pregnancy due to the PPCM diagnosis, and one was put on low-dose aspirin to prevent pre-eclampsia in her subsequent pregnancy.
There were no maternal deaths, but at 7 weeks postpartum one of the seven women (14%) experienced relapse and deterioration of LVEF to 45%, although she had only vague symptoms of heart failure. She was treated with an oral angiotensin-converting enzyme-inhibitor and an oral beta-blocker and LVEF normalised approximately 8 months after the relapse. Heart failure medication was continued for 2.5 years after the relapse diagnosis. This woman had the lowest LVEF (22%) of all the seven women at the time of PPCM diagnosis and reduced LVEF (48%) at the 12-month follow up. Her index pregnancy was complicated by gestational hypertension. Time to normalised LVEF after the index pregnancy was 24 months.
No women were treated with the prolactin-inhibitor bromocriptine to prevent relapse, but one woman received 0.5 mg cabergoline twice daily for 2 days to inhibit lactation due to medical treatment for a non-cardiac comorbidity. At least four women initiated breastfeeding and the one woman who had a relapse was breastfeeding at the time of her relapse, but more detailed information about frequency and duration of breastfeeding was not reported in the hospital records reviewed.
Neonatal outcomes were good with no babies being small-for-gestational-age, having congenital malformations or other neonatal complications.
All women had a stable and normal LVEF during and after the subsequent pregnancy, except for the one who had a relapse of heart failure postpartum. This is further described in Figure S2 , which illustrates the time-course of recorded left ventricular ejection fractions for the women who continued a subsequent pregnancy beyond 20 weeks of gestation. LVEF, left ventricular ejection fraction; PPCM, peripartum cardiomyopathy. Comorbidities: asthma (n = 6), thyroid disease (n = 3), chronic hypertension (n = 2), depression (n = 2), epilepsy (n = 2), rheumatoid arthritis (n = 2), ADAMTS13 deficiency (n = 1), antiphospholipid syndrome (n = 1), Crohn's disease (n = 1), and factor V Leiden mutation (n = 1). Major adverse events: death, heart transplantation, mechanic circulatory support or persistent heart failure with left ventricular ejection fraction ≤35%.
Sterilisation was performed in four of the 61 women with PPCM (6.6%), all multiparous, at a median age of 36 years (32-41) and at a median of 33 months after the initial PPCM diagnosis. Three of the four women had been advised against a new pregnancy after the PPCM diagnosis because of the risk of recurrence. They presented with a median LVEF of 29% at PPCM diagnosis and had a median LVEF of 54% (42-60) at the 12-month follow up after their index pregnancy. None of the women had major adverse events such as the need for advanced heart failure therapy with inotropics, mechanical circulatory support, heart transplantation or persistent severe heart failure in relation to the index pregnancy and initial PPCM diagnosis.
Discussion

Main findings
Of 61 women with PPCM, 13 (21%) had a total of 16 subsequent pregnancies resulting in one miscarriage, seven early terminations, one ectopic pregnancy, and seven liveborn children. Women who had a subsequent pregnancy and gave birth may represent a subgroup of younger women with milder courses of PPCM, but differences were not statistically significant. There were no maternal deaths or significant cardiac events during pregnancy, but one woman (14%), who gave birth to a liveborn child, had relapse 7 weeks postpartum. None of the six women who had a first-trimester termination, experienced relapse of PPCM.
Of the 13 women with a subsequent pregnancy, 62% had been advised against a new pregnancy before the subsequent pregnancy due to the risk of relapse. A total of four women (6.6%) were sterilised.
Strengths and limitations
This is the first nationwide study of subsequent reproductive outcomes in women with PPCM. We adhered to a stringent identification process with the use of nationwide registries, review of patient records and validation of registry diagnoses, thereby reducing the risk of recall and selection bias. PPCM is a rare disease and women are often counselled against future pregnancies. Hence, both the parent study population and the population in our study are relatively small. Elkayam et al. 16 reviewed 10 cohorts with five to 35 subsequent pregnancies and Hilfiker-Kleiner et al. 6 recently reported on 34 subsequent pregnancies. In this context, we believe our medium-sized populationbased cohort adds information to the topic.
The retrospective study design has some limitations such as inaccessible, incomplete or missing data. Information on breastfeeding and pharmacological inhibition of lactation 1 (17) 1 (14) 1 Women on heart failure medication at the beginning of their subsequent pregnancy, n (%)
3 (50) 2 (29) 0.242 NYHA functional class I before new pregnancy, n (%) 6 (100) 7 (100) 1 Advised against new pregnancy, n (%) 6 (100) 2 (29) 0.061 HDP, hypertensive disorder of pregnancy: gestational hypertension, pre-eclampsia, HELLP syndrome or eclampsia; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PPCM, peripartum cardiomyopathy. *Black African. **Inotropic therapy. ***Advanced heart failure therapy: inotropic therapy, mechanical circulatory support or heart transplantation. would be of special interest as the nursing hormone prolactin is involved in PPCM pathophysiology, 4 but these data were not sufficiently recorded in the patient records to be included in our analysis. Furthermore, we were not able to retrieve all detailed echocardiographic reports. Several times, LVEF was stated as being 'normal' in the medical record, and we interpreted all 'normal' LVEFs as being ≥55%. Also, our follow-up period is relatively short. To our knowledge, no studies have yet been published evaluating the long-term impact of subsequent pregnancy on cardiac morbidity and mortality.
Interpretation
Relapse and mortality rates vary in studies regarding subsequent pregnancies after a history of PPCM. In the latest review from 2014, Elkayam et al. 16 reviewed ten studies where a total of 93 subsequent pregnancies were reported, all among women with persistent left ventricular dysfunction before a subsequent pregnancy. In this group, a mean relapse rate of 48% was found across studies; 39% had persistently decreased LVEF at follow up after the subsequent pregnancy and 16% of the women died. Another 98 subsequent pregnancies were reported among women who entered the new pregnancy with full recovery of left ventricular function. A mean relapse rate of 27% was noted in this group, with 13% having persistently decreased LVEF at follow up, but there were no maternal deaths. A study by Shani et al. 21 was not included in the review and reported 14 subsequent pregnancies among nine women in Israel. Five pregnancies resulted in early miscarriages and nine pregnancies proceeded to term. All but one woman had recovered left ventricular function before the subsequent pregnancy. Of the eight women with recovered left ventricular function, two women (25%) had transient cardiac complications. The one woman without recovery before the subsequent pregnancy, deteriorated and eventually died. Mishra et al. 22 reported on nine Indian women with a history of PPCM and a subsequent pregnancy. All women entered the subsequent pregnancy with symptoms of heart failure and a mean reduced LVEF of 39%. At least five of them (56%) deteriorated during the subsequent pregnancy and all these died of severe heart failure. In a recent prospective study, Hilfiker-Kleiner et al. 6 reported on subsequent pregnancies among 34 women with previous PPCM from South Africa, Germany and Scotland. Almost half of the women entered a subsequent pregnancy with left ventricular dysfunction, of whom 69% had a relapse defined as incomplete recovery 6 months after the subsequent pregnancy, whereas only 44% of women with recovered left ventricular function before the subsequent pregnancy had a relapse. Mortality was 25% among nonrecovered women compared with no deaths among women who had recovered fully before the subsequent pregnancy.
The authors concluded that addition of bromocriptine to standard heart failure therapy improved the outcome in a subsequent pregnancy in their cohort, but this has been debated. 23 Taking these results together with our new data, the reported relapse among women with full recovery of LVEF after the index pregnancy ranges from 14 to 44% with no reported deaths. 6, 16, 21 Reported relapse among women with persistent left ventricular dysfunction ranges from 48 to 69% when single case reports are excluded with an associated mortality of 16-56%. 6, 16, 22 Clearly, persistent left ventricular dysfunction following PPCM is a strong and probably the strongest risk factor for relapse in a subsequent pregnancy, but other risk factors have yet to be explored.
Pre-eclampsia and PPCM share several pathophysiological mechanisms including endothelial damage and increased levels of the placental protein soluble Fms-like tyrosine kinase-1 (sFlt-1). 2, 4 Up to 50% of women with PPCM have experienced a hypertensive disorder during the index pregnancy and women with PPCM have an odds ratio of 4 of suffering concomitant pre-eclampsia compared with a population-based background risk. 3, 24 Several studies have found that women with PPCM and concomitant hypertensive disorders of pregnancy have a more favourable outcome, suggesting that hypertensive disorders of pregnancy could be a prognostic protective factor, 8, 9, 18, 25, 26 but conflicting results on the impact of pre-eclampsia on PPCM prognosis exist. 12, 27, 28 The role of concomitant hypertensive disorders of pregnancy in subsequent pregnancies is unknown, and our small sample size did not allow us to determine whether hypertensive disorders of pregnancy in the index pregnancy lead to a more favourable outcome in a subsequent pregnancy.
A subsequent pregnancy requires careful multidisciplinary counselling and management strategies before and during pregnancy. Currently, it is difficult to predict relapse, especially among women with recovered LVEF. Lampert et al. 29 used a dobutamine-induced stress echocardiography to reveal a decreased contractile reserve in women with a history of PPCM and recovered left ventricular function (LVEF > 50%). This indicated a subclinical abnormality of the left ventricular function that may be reactivated during the haemodynamic stress of a subsequent pregnancy. It has been suggested that an echocardiography, during exercise or dobutamine-induced stress, could be a useful method to assess cardiac contractile reserve function and estimate the risk associated with a subsequent pregnancy. [29] [30] [31] Further studies are required to determine the clinical utility of these investigations in this setting.
Accumulating data suggest that women with a persistently reduced LVEF following PPCM have a substantial risk (48-69%) of further deterioration if they undertake another pregnancy, and care should be taken that they and their families are fully aware of this when they are considering whether to have another child. If the LVEF has recovered fully, the risk of deterioration is lower, but estimates range from 14 to 44% and therefore detailed pre-pregnancy counselling is still required, ideally at a multidisciplinary clinic involving both obstetricians and cardiologists with experience of caring for women with PPCM.
Conclusion
In this nationwide study of 61 women with PPCM, 13 women (21%) subsequently became pregnant and seven (11%) gave birth to a healthy liveborn child. Of these seven, only one woman (14%) experienced deterioration in her LVEF. There were no maternal deaths. The results underscore how relapse of PPCM may occur in subsequent pregnancies, even in women with full LVEF recovery. More research, preferably multicentre studies, is needed to identify predictors of relapse and evaluate the effect of subsequent pregnancies on long-term outcome for PPCM women.
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